---
title: "CDK2 Inhibition in Aneuploid Cancers: Efficacy, Residual Polyploid Resistance, and Combination Str"
id: "pubmed-42100802"
canonical_url: "https://medichelpline.com/clinical-feed/pubmed-42100802"
content_type: "clinical_feed_article"
specialty: "Pharmacology"
source_name: "PubMed / NCBI"
source_url: "https://pubmed.ncbi.nlm.nih.gov/42100802/"
doi: "10.1158/1535-7163.MCT-26-0181"
published_at: "2026-09-02T00:00:00.000Z"
evidence_level: "Journal Article"
license: "CC-BY-NC-4.0 / Informational Use"
---
# CDK2 Inhibition in Aneuploid Cancers: Efficacy, Residual Polyploid Resistance, and Combination Str
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/pubmed-42100802
- **Specialty:** [Pharmacology](https://medichelpline.com/clinical-feed/pharmacology.md)
- **Primary Source:** PubMed / NCBI
- **Source URL:** [Original Journal Publication](https://pubmed.ncbi.nlm.nih.gov/42100802/)
- **DOI:** [10.1158/1535-7163.MCT-26-0181](https://doi.org/10.1158%2F1535-7163.MCT-26-0181)
- **Published At:** 2026-09-02T00:00:00.000Z
- **Evidence Rating:** Journal Article
## Executive GIST (TL;DR)
- Aneuploidy is a common hallmark of human cancers that promotes drug resistance and aggressive behavior. Targeting features of aneuploid tumors is therefore therapeutically relevant. - Inhibition of **CDK2** triggers a programmed mitotic death termed **anaphase catastrophe**, which selectively induces apoptosis in aneuploid cancer cells while sparing non-aneuploid epithelial cells, offering a favorable therapeutic window. - Despite effective induction of apoptosis in many aneuploid cells, a residual population of **polyploid** cancer cells persists after **CDK2** antagonism in both in vitro and in vivo models. - The surviving polyploid cells are resistant to apoptosis driven by **CDK2** inhibition, providing a plausible mechanism for clinical drug resistance and limiting eradication of tumors by single-agent CDK2 inhibitors. - Isolated apoptosis-resistant polyploid cells show enrichment for **CDK1** expression and for several kinesin superfamily proteins (**KIFs**), suggesting alternative survival pathways are engaged. - Combining **CDK2** inhibition with antagonists targeting **CDK1** or specific **KIF** proteins markedly increases anticancer activity in aneuploid models, overcoming the resistance of the polyploid subset in preclinical studies. - The review proposes that clinically tractable combined regimens (CDK2 inhibitors plus CDK1 or KIF antagonists) warrant evaluation in future clinical trials to attempt eradication of aneuploid cancers after initial CDK2 antagonism. - Details such as specific drug names, dosing regimens, exact experimental models, and clinical trial designs were not reported in the source abstract and would require consulting the full text for full methodological and translational specifics.
## Clinical Analysis & Structured Key Points
Clipboard, Search History, and several other advanced features are temporarily unavailable. [ Skip to main page content ](https://pubmed.ncbi.nlm.nih.gov/42100802/#article-details) ![U.S. flag](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png) An official website of the United States government Here's how you know ![Dot gov](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg) **The .gov means it’s official.** Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site. ![Https](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg) **The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. [ ![NIH NLM Logo](https://cdn.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg) ](https://www.ncbi.nlm.nih.gov/) [Log in](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42100802%2F) Show account info Close #### Account Logged in as: **username** * [Dashboard](https://www.ncbi.nlm.nih.gov/myncbi/) * [Publications](https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/) * [Account settings](https://www.ncbi.nlm.nih.gov/account/settings/) * [Log out](https://www.ncbi.nlm.nih.gov/account/signout/?back_url=https%3A//pubmed.ncbi.nlm.nih.gov/42100802/) [Access keys](https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys) [NCBI Homepage](https://www.ncbi.nlm.nih.gov) [MyNCBI Homepage](https://pubmed.ncbi.nlm.nih.gov/myncbi/) [Main Content](https://pubmed.ncbi.nlm.nih.gov/42100802/#maincontent) [Main Navigation](https://pubmed.ncbi.nlm.nih.gov/42100802/) [ ![pubmed logo](https://cdn.ncbi.nlm.nih.gov/pubmed/af7de7da-df5d-41c6-8de4-8c266af8ccfb/core/images/pubmed-logo-blue.svg) ](https://pubmed.ncbi.nlm.nih.gov/) [ ](https://pubmed.ncbi.nlm.nih.gov/42100802/ "Show search bar") Search: [](https://pubmed.ncbi.nlm.nih.gov/42100802/ "Clear search input")Search [Advanced](https://pubmed.ncbi.nlm.nih.gov/advanced/) [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/clipboard/) [ User Guide ](https://pubmed.ncbi.nlm.nih.gov/help/) Save Email Send to * [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/42100802/) * [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42100802%2F%23open-bibliography-panel) * [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42100802%2F%23open-collections-panel) * [Citation manager](https://pubmed.ncbi.nlm.nih.gov/42100802/) Display options Display options Format Abstract PubMed PMID ## Save citation to file Format: Summary (text) PubMed PMID Abstract (text) CSV Create file Cancel ## Email citation Email address has not been verified. Go to [ My NCBI account settings ](https://account.ncbi.nlm.nih.gov/settings/) to confirm your email and then refresh this page. To: Subject: Body: Format: Summary Summary (text) Abstract Abstract (text) MeSH and other data Send email Cancel ### Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42100802/) Add Cancel ### Add to My Bibliography * My Bibliography Unable to load your delegates due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42100802/) Add Cancel ## Your saved search Name of saved search: Search terms: [Test search terms](https://pubmed.ncbi.nlm.nih.gov/42100802/) Would you like email updates of new search results? Saved Search Alert Radio Buttons * Yes * No Email: ([change](https://www.ncbi.nlm.nih.gov/account/settings/)) Frequency: Monthly Weekly Daily Which day? The first Sunday The first Monday The first Tuesday The first Wednesday The first Thursday The first Friday The first Saturday The first day The first weekday Which day? Sunday Monday Tuesday Wednesday Thursday Friday Saturday Report format: Summary Summary (text) Abstract Abstract (text) PubMed Send at most: 1 item 5 items 10 items 20 items 50 items 100 items 200 items Send even when there aren't any new results Optional text in email: Save Cancel ## Create a file for external citation management software Create file Cancel ## Your RSS Feed Name of RSS Feed: Number of items displayed: 5 10 15 20 50 100 Create RSS Cancel RSS Link Copy ### Full text links [![Silverchair Information Systems full text link](https://cdn.ncbi.nlm.nih.gov/corehtml/query/egifs/https:--aacrjournals.org-images-pubmed-molcanther_full.gif) Silverchair Information Systems ](https://aacrjournals.org/mct/article-lookup/doi/10.1158/1535-7163.MCT-26-0181 "See full text options at Silverchair Information Systems") [ Full text links ](https://pubmed.ncbi.nlm.nih.gov/42100802/) ### Actions Cite Collections Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42100802/) Add Cancel Permalink Permalink Copy Display options Display options Format Abstract PubMed PMID ### Page navigation * [ Title & authors ](https://pubmed.ncbi.nlm.nih.gov/42100802/#heading) * [ Abstract ](https://pubmed.ncbi.nlm.nih.gov/42100802/#abstract) * [Similar articles](https://pubmed.ncbi.nlm.nih.gov/42100802/#similar) * [ Publication types ](https://pubmed.ncbi.nlm.nih.gov/42100802/#publication-types) * [ MeSH terms ](https://pubmed.ncbi.nlm.nih.gov/42100802/#mesh-terms) * [ Substances ](https://pubmed.ncbi.nlm.nih.gov/42100802/#substances) * [Related information](https://pubmed.ncbi.nlm.nih.gov/42100802/#related-links) * [ Grants and funding ](https://pubmed.ncbi.nlm.nih.gov/42100802/#grants) * [ LinkOut - more resources ](https://pubmed.ncbi.nlm.nih.gov/42100802/#linkout) Title & authors Abstract Similar articles Publication types MeSH terms Substances Related information Grants and funding LinkOut - more resources Review Mol Cancer Ther Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Mol+Cancer+Ther%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Mol+Cancer+Ther%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42100802/) . 2026 Sep 2;25(9):1447-1454. doi: 10.1158/1535-7163.MCT-26-0181. # CDK2 Inhibition and Eradication of Aneuploid Cancers: Promise Meets Resistance [Samuel C Okpechi](https://pubmed.ncbi.nlm.nih.gov/?term=Okpechi+SC&cauthor_id=42100802)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42100802/#full-view-affiliation-1 "Molecular Pharmacology Program, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland."), [Zibo Chen](https://pubmed.ncbi.nlm.nih.gov/?term=Chen+Z&cauthor_id=42100802)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42100802/#full-view-affiliation-1 "Molecular Pharmacology Program, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland."), [Liliya Tyutyunyk-Massey](https://pubmed.ncbi.nlm.nih.gov/?term=Tyutyunyk-Massey+L&cauthor_id=42100802)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42100802/#full-view-affiliation-1 "Molecular Pharmacology Program, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland."), [Yair Alfaro](https://pubmed.ncbi.nlm.nih.gov/?term=Alfaro+Y&cauthor_id=42100802)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42100802/#full-view-affiliation-1 "Molecular Pharmacology Program, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland.")[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42100802/#full-view-affiliation-2 "Tecnológico de Monterrey , Mexico City, Mexico."), [Xi Liu](https://pubmed.ncbi.nlm.nih.gov/?term=Liu+X&cauthor_id=42100802)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42100802/#full-view-affiliation-1 "Molecular Pharmacology Program, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland."), [Ethan Dmitrovsky](https://pubmed.ncbi.nlm.nih.gov/?term=Dmitrovsky+E&cauthor_id=42100802)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42100802/#full-view-affiliation-1 "Molecular Pharmacology Program, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland.") Affiliations Expand ### Affiliations * 1 Molecular Pharmacology Program, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland. * 2 Tecnológico de Monterrey , Mexico City, Mexico. * PMID: **42100802** * DOI: [ 10.1158/1535-7163.MCT-26-0181 ](https://doi.org/10.1158/1535-7163.mct-26-0181) Item in Clipboard Review # CDK2 Inhibition and Eradication of Aneuploid Cancers: Promise Meets Resistance Samuel C Okpechi et al. Mol Cancer Ther. 2026. Show details Display options Display options Format Abstract PubMed PMID Mol Cancer Ther Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Mol+Cancer+Ther%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Mol+Cancer+Ther%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42100802/) . 2026 Sep 2;25(9):1447-1454. doi: 10.1158/1535-7163.MCT-26-0181. ### Authors [Samuel C Okpechi](https://pubmed.ncbi.nlm.nih.gov/?term=Okpechi+SC&cauthor_id=42100802)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42100802/#short-view-affiliation-1 "Molecular Pharmacology Program, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland."), [Zibo Chen](https://pubmed.ncbi.nlm.nih.gov/?term=Chen+Z&cauthor_id=42100802)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42100802/#short-view-affiliation-1 "Molecular Pharmacology Program, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland."), [Liliya Tyutyunyk-Massey](https://pubmed.ncbi.nlm.nih.gov/?term=Tyutyunyk-Massey+L&cauthor_id=42100802)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42100802/#short-view-affiliation-1 "Molecular Pharmacology Program, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland."), [Yair Alfaro](https://pubmed.ncbi.nlm.nih.gov/?term=Alfaro+Y&cauthor_id=42100802)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42100802/#short-view-affiliation-1 "Molecular Pharmacology Program, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland.")[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42100802/#short-view-affiliation-2 "Tecnológico de Monterrey , Mexico City, Mexico."), [Xi Liu](https://pubmed.ncbi.nlm.nih.gov/?term=Liu+X&cauthor_id=42100802)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42100802/#short-view-affiliation-1 "Molecular Pharmacology Program, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland."), [Ethan Dmitrovsky](https://pubmed.ncbi.nlm.nih.gov/?term=Dmitrovsky+E&cauthor_id=42100802)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42100802/#short-view-affiliation-1 "Molecular Pharmacology Program, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland.") ### Affiliations * 1 Molecular Pharmacology Program, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland. * 2 Tecnológico de Monterrey , Mexico City, Mexico. * PMID: **42100802** * DOI: [ 10.1158/1535-7163.MCT-26-0181 ](https://doi.org/10.1158/1535-7163.mct-26-0181) Item in Clipboard Full text links Cite Display options Display options Format Abstract PubMed PMID ## Abstract Aneuploidy is a cancer hallmark that causes resistance to anticancer drugs and promotes aggressive tumors. Thus, aneuploidy is a consequential feature of human malignancy. This review addresses how cyclin-dependent kinase 2 (CDK2) inhibition targets a broad array of aneuploid cancers for proapoptotic death by engaging a death program called anaphase catastrophe. This program eliminates aneuploid cancers while sparing non-aneuploid epithelial cells, thereby providing a favorable therapeutic window. Despite CDK2 inhibition, a residual population of polyploid cancer cells persists in both in vitro and in vivo settings. This polyploid cancer cell population is resistant to apoptosis conferred by CDK2 inhibition of aneuploid cancers. This provides a basis for clinical drug resistance. The triggering apoptotic death of aneuploid cancers via CDK2 antagonism is compromised by the presence of this apoptosis-resistant population. To elucidate the nature of this polyploid population, these apoptotic-resistant cells were isolated and were found enriched for expressed cyclin-dependent kinase 1 (CDK1) and kinesin superfamily proteins (KIFs). Intriguingly, combining CDK2 inhibition with antagonists for CDK1 or KIF species markedly promoted anticancer effects in aneuploid cancers. This clinically-tractable combined regimen is hypothesized to expose aneuploid cancers to eradication after CDK2 antagonism. Future clinical trials should explore this possibility. ©2026 American Association for Cancer Research. [PubMed Disclaimer](https://pubmed.ncbi.nlm.nih.gov/disclaimer/) ## Similar articles * [ Engaging Anaphase Catastrophe Mechanisms to Eradicate Aneuploid Cancers. ](https://pubmed.ncbi.nlm.nih.gov/29559545/) Kawakami M, Mustachio LM, Liu X, Dmitrovsky E.Kawakami M, et al.Mol Cancer Ther. 2018 Apr;17(4):724-731. doi: 10.1158/1535-7163.MCT-17-1108. Epub 2018 Mar 20.Mol Cancer Ther. 2018.PMID: 29559545Free PMC article.Review. * [ CDK2 inhibition disorders centrosome stoichiometry and alters cellular outcomes in aneuploid cancer cells. ](https://pubmed.ncbi.nlm.nih.gov/38031910/) Chen Z, Liu X, Kawakami M, Liu X, Baker A, Bhatawadekar A, Tyutyunyk-Massey L, Narayan K, Dmitrovsky E.Chen Z, et al.Cancer Biol Ther. 2023 Dec 31;24(1):2279241. doi: 10.1080/15384047.2023.2279241. Epub 2023 Nov 30.Cancer Biol Ther. 2023.PMID: 38031910Free PMC article. * [ TRIGGERING ANAPHASE CATASTROPHE TO COMBAT ANEUPLOID CANCERS. ](https://pubmed.ncbi.nlm.nih.gov/32675848/) Dmitrovsky E, Kawakami M, Liu XI, Freemantle SJ, Kurie JM.Dmitrovsky E, et al.Trans Am Clin Climatol Assoc. 2020;131:82-94.Trans Am Clin Climatol Assoc. 2020.PMID: 32675848Free PMC article. * [ A Novel CDK2/9 Inhibitor CYC065 Causes Anaphase Catastrophe and Represses Proliferation, Tumorigenesis, and Metastasis in Aneuploid Cancers. ](https://pubmed.ncbi.nlm.nih.gov/33277443/) Kawakami M, Mustachio LM, Chen Y, Chen Z, Liu X, Wei CH, Roszik J, Kittai AS, Danilov AV, Zhang X, Fang B, Wang J, Heymach JV, Tyutyunyk-Massey L, Freemantle SJ, Kurie JM, Liu X, Dmitrovsky E.Kawakami M, et al.Mol Cancer Ther. 2021 Mar;20(3):477-489. doi: 10.1158/1535-7163.MCT-19-0987. Epub 2020 Dec 4.Mol Cancer Ther. 2021.PMID: 33277443Free PMC article. * [ Cyclin E and its low molecular weight forms in human cancer and as targets for cancer therapy. ](https://pubmed.ncbi.nlm.nih.gov/14508079/) Akli S, Keyomarsi K.Akli S, et al.Cancer Biol Ther. 2003 Jul-Aug;2(4 Suppl 1):S38-47.Cancer Biol Ther. 2003.PMID: 14508079Review. [ See all similar articles ](https://pubmed.ncbi.nlm.nih.gov/?linkname=pubmed_pubmed&from_uid=42100802) ## Publication types * Review Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Review%22%5Bpt%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Review) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42100802/) ## MeSH terms * Aneuploidy* Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Aneuploidy%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Aneuploidy) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42100802/) * Animals Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Animals%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Animals) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42100802/) * Antineoplastic Agents* / pharmacology Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Antineoplastic+Agents%2Fpharmacology%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Antineoplastic+Agents) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42100802/) * Antineoplastic Agents* / therapeutic use Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Antineoplastic+Agents%2Ftherapeutic+use%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Antineoplastic+Agents) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42100802/) * Apoptosis / drug effects Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Apoptosis%2Fdrug+effects%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Apoptosis) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42100802/) * Cyclin-Dependent Kinase 2* / antagonists & inhibitors Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Cyclin-Dependent+Kinase+2%2Fantagonists+and+inhibitors%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Cyclin-Dependent+Kinase+2) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42100802/) * Cyclin-Dependent Kinase 2* / metabolism Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Cyclin-Dependent+Kinase+2%2Fmetabolism%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Cyclin-Dependent+Kinase+2) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42100802/) * Drug Resistance, Neoplasm* / genetics Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Drug+Resistance%2C+Neoplasm%2Fgenetics%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Drug+Resistance%2C+Neoplasm) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42100802/) * Humans Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Humans%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Humans) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42100802/) * Molecular Targeted Therapy Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Molecular+Targeted+Therapy%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Molecular+Targeted+Therapy) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42100802/) * Neoplasms* / drug therapy Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Neoplasms%2Fdrug+therapy%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Neoplasms) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42100802/) * Neoplasms* / genetics Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Neoplasms%2Fgenetics%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Neoplasms) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42100802/) * Neoplasms* / metabolism Ac
## Related Clinical Research

- [Ambient light during sample processing causes verteporfin-driven protein cross-linking](https://medichelpline.com/clinical-feed/plos-one-17-ambient-light-drives-verteporfin-induced-protein-cross-linking-during-standard.md)
- [Site-Specific ApoA‑I Glycation Impairs HDL Function and May Promote Atherosclerosis in Diabetes](https://medichelpline.com/clinical-feed/pubmed-42639673.md) (DOI: 10.1161/CIRCULATIONAHA.125.078171)
- [GRK2 phosphorylation of AdipoR1 Ser205 drives diabetic cardiomyopathy; S205A mutation restores adi](https://medichelpline.com/clinical-feed/pubmed-42763212.md) (DOI: 10.3760/cma.j.cn112137-20260508-01227)
- [FDA Revises Nonclinical Testing Rules to Advance Alternatives to Animal Studies](https://medichelpline.com/clinical-feed/fda-news-releases-0-fda-updates-regulations-to-advance-innovative-alternatives-to-animal-testing.md)
- [3-Hydroxypropanamidines: From Antiplasmodial Leads to a Novel Antibacterial Scaffold](https://medichelpline.com/clinical-feed/biorxiv-15-3-hydroxypropanamidines-from-antiplasmodial-leads-to-a-novel-antibacterial.md)

## Navigation
- [← Back to Pharmacology Feed](https://medichelpline.com/clinical-feed/pharmacology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.